GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (STU:MBP) » Definitions » Cyclically Adjusted PB Ratio

Protagenic Therapeutics (STU:MBP) Cyclically Adjusted PB Ratio : 0.26 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Protagenic Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Protagenic Therapeutics's current share price is €1.42. Protagenic Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €5.44. Protagenic Therapeutics's Cyclically Adjusted PB Ratio for today is 0.26.

The historical rank and industry rank for Protagenic Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:MBP' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.27
Current: 0.23

During the past years, Protagenic Therapeutics's highest Cyclically Adjusted PB Ratio was 0.27. The lowest was 0.00. And the median was 0.00.

STU:MBP's Cyclically Adjusted PB Ratio is ranked better than
80.7% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:MBP: 0.23

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Protagenic Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €0.442. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.44 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Protagenic Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Protagenic Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Cyclically Adjusted PB Ratio Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.15

Protagenic Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.29 0.27 0.15 0.26

Competitive Comparison of Protagenic Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Protagenic Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Cyclically Adjusted PB Ratio falls into.



Protagenic Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Protagenic Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.42/5.44
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Protagenic Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.442/131.7762*131.7762
=0.442

Current CPI (Mar. 2024) = 131.7762.

Protagenic Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 -2.923 100.560 -3.830
201409 -16.462 100.428 -21.601
201412 -33.846 99.070 -45.020
201503 -55.538 99.621 -73.464
201506 -68.769 100.684 -90.006
201509 -86.769 100.392 -113.895
201512 -111.846 99.792 -147.693
201603 416.615 100.470 546.429
201606 131.784 101.688 170.777
201609 1.261 101.861 1.631
201612 0.916 101.863 1.185
201703 0.794 102.862 1.017
201706 0.651 103.349 0.830
201709 0.550 104.136 0.696
201712 0.402 104.011 0.509
201803 0.305 105.290 0.382
201806 0.187 106.317 0.232
201809 0.108 106.507 0.134
201812 -0.072 105.998 -0.090
201903 -0.125 107.251 -0.154
201906 -0.131 108.070 -0.160
201909 -0.129 108.329 -0.157
201912 -0.223 108.420 -0.271
202003 -0.207 108.902 -0.250
202006 -0.258 108.767 -0.313
202009 -0.335 109.815 -0.402
202012 -0.365 109.897 -0.438
202103 -0.628 111.754 -0.741
202106 2.204 114.631 2.534
202109 2.080 115.734 2.368
202112 2.045 117.630 2.291
202203 1.836 121.301 1.995
202206 1.808 125.017 1.906
202209 1.725 125.227 1.815
202212 1.511 125.222 1.590
202303 1.386 127.348 1.434
202306 1.154 128.729 1.181
202309 0.898 129.860 0.911
202312 0.758 129.419 0.772
202403 0.442 131.776 0.442

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Protagenic Therapeutics  (STU:MBP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Protagenic Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics (STU:MBP) Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics (STU:MBP) Headlines

No Headlines